Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Sorafenib in Recurrent or Metastatic Triple Negative Breast Cancer
NCT02624700Phase 2Terminated
- Sponsor
- Virginia Commonwealth University
- Start
- Jan 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, sorafenib in triple-negative breast cancer (TNBC), sponsored by Virginia Commonwealth University. Started Jan 2016; status: terminated.
02
Drugs
pemetrexedsorafenib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02624700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624700.